Association between Active Mobility Index and sarcopenia among Japanese community-dwelling older adults

Satoshi Kurita1*, Takehiko Doi1, Kota Tsutsumimoto1, Sho Nakakubo1, Yuto Kiuchi1,2, Kazuhei Nishimoto1,3 & Hiroyuki Shimada1

1Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan; 2Graduate School of Health Sciences, Kagoshima University, Kagoshima, Japan; 3Department of Medical Sciences, Medical Science Division, Graduate School of Medicine, Science and Technology, Shinshu University, Matsumoto, Japan

Abstract

Background A physically active lifestyle, including physical and social activities, is needed to maintain muscle mass, strength, and physical performance. A large life space characterizes an active lifestyle, but the association between life space with physical and social activities and sarcopenia is unclear. This study aimed to examine the association between life space with physical and social activities, assessed using the Active Mobility Index (AMI), and sarcopenia in community-dwelling Japanese older adults.

Methods This study used a large, cross-sectional cohort dataset from the National Center for Geriatrics and Gerontology-Study of Geriatric Syndromes (NCGG-SGS). Between 2013 and 2018, community-dwelling Japanese adults aged ≥60 years participated in the NCGG-SGS. Sarcopenia was identified by measuring muscle mass and strength based on the clinical definition. The secondary outcomes were sarcopenia indices, including lower muscle mass, lower muscle strength, and lower gait speed. AMI assessed life space with physical and social activities in each life space (distance from the respondent’s home: <1, 1–10, or >10 km) during the past month by noting the frequency, primary purpose, type of transportation, interaction with others, and physical activity. The associations between quartile groups of AMI total, physical, and social scores and sarcopenia were examined using a logistic regression model.

Results From all participants, 21,644 participants (age 73.5 ± 5.8 years, 54.7% female) were included in the analysis. The prevalence of sarcopenia was 4.1% (n = 894). For the AMI total score, referred to Q1 group, Q3 and Q4 groups were significantly associated with a reduced odds ratio (OR) of sarcopenia after adjusting for all covariates [adjusted OR (aOR) (95% confidence interval), Q3: 0.71 (0.57–0.89), Q4: 0.69 (0.55–0.87)]. Q3 and Q4 of the AMI physical score groups were also significantly associated with reduced OR of sarcopenia [Q3: 0.71 (0.57–0.89), Q4: 0.67 (0.54–0.84)]. For the AMI social score, only the Q4 group showed reduced OR for sarcopenia [0.79 (0.62–1.01)]. Q3 and Q4 of the AMI total score and physical score were associated with reduced OR of all sarcopenia indices (aOR 0.55–0.82, all P < 0.05), whereas Q4 of AMI social score was associated with all indices (aOR 0.85–0.81, all P < 0.05).

Conclusions The extent of life space with physical activity was associated with sarcopenia in community-dwelling older adults. A longitudinal study is needed to examine whether life space with physical and social activities affect the development of sarcopenia.

Keywords Life space; Physical activity; Social activity; Musculoskeletal disease

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Sarcopenia is an age-related loss of skeletal muscle mass and strength and is formally recognized as a muscle disease with an ICD-10-MC Diagnosis Code, M62.84.1,2 Sarcopenia is a critical issue for older adults because it leads to a lack of independence and increased risk of falls, hospitalization, osteoporosis, cardiovascular diseases, disability, and mortality.3,4 Among the risk factors for sarcopenia, inactivity is a modifiable factor, and enhancement of activity is expected to assist in coping with sarcopenia.5

An active lifestyle is needed to maintain muscle mass, strength, and physical performance. The importance of physical activity in sarcopenia has already been clarified.6–8 In addition, previous studies report that engagement in social activity reduces the risk of mobility disability and motor decline, including gait speed, balance, and muscle strength.9–11 A large life space, which has also been regarded as an essential factor for older adults’ health, is crucial for an active lifestyle later in life.12 Life space is defined as movement extending from within one’s home to move beyond one’s town or geographic region over a specified period.13 Larger life space is associated with greater engagement in physical activity,14,15 and social involvement,16,17 and constrained life space is thought to cause further loss of physiological reserve, capacity, and frailty.18 In a cross-sectional study, life space mobility was associated with variables related to frailty.19 Although life space would associate with sarcopenia and its indices, the association is unclear. Furthermore, simultaneous evaluation of life space and related activities helps assess the risk of disability.20 The Active Mobility Index (AMI) assesses physical and social activities in each life space.20 Therefore, this study aimed to examine the associations between life space for physical and social activities assessed by the AMI and sarcopenia among community-dwelling older adults.

Methods

Participants

This study used a cross-sectional cohort dataset from the National Center for Geriatrics and Gerontology-Study of Geriatric Syndromes (NCGG-SGS). The NCGG-SGS is a community-based cohort study to establish a screening programme for geriatric syndromes and validate evidence-based interventions for their prevention.21 From the NCGG-SGS, community-dwelling older people aged ≥60 years were recruited from Obu City, Midori Ward of Nagoya City, Takahama City, Tokai City, and Toyoake City in Aichi Prefecture, Japan. A total of 25,851 individuals were eligible for this study.

In the present study, participants were excluded if they had a self-reported basic activity of daily living (BADL) disability (n = 70); a medical history that included stroke, dementia, depression, or Parkinson’s disease (n = 2316); a general cognitive impairment [Mini-Mental State Examination (MMSE) score < 21; n = 472]22; or missing data for all the variables (n = 1239). A total of 21,644 participants were included in the analysis. All participants provided written informed consent. This study was conducted according to the Declaration of Helsinki guidelines. The National Center for Geriatrics and Gerontology research ethics committee approved the study protocol.

Measurement

Sarcopenia

Sarcopenia was identified by both to muscle mass and muscle strength according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) recommendations.3 We adopted cut-off values for each variable in the revised Asian Working Group for Sarcopenia criteria: low muscle mass defined by skeletal muscle mass index (SMI) < 7.0 kg/m² in men and <5.7 kg/m² in women and low muscle strength defined by handgrip strength < 28 kg in men and <18 kg in women.23 In addition, because EWGSOP2 considers poor physical performance as a severe sarcopenia indicator, sarcopenia indices including low SMI, low muscle strength, and low gait speed (<1.0 m/s)23 were set as outcomes for subanalyses.

Skeletal muscle mass was assessed using a multifrequency bioelectrical impedance analyser (MC-980A and MC-780A; TANITA, Tokyo, Japan). The participants grasped the surface of the hand electrode by each of the five fingers and placed heels and toes within a circular-shaped foot electrode. Participants were instructed to extend their limbs during the measurements and avoid touching any other body part. Six electrical frequencies (1, 5, 50, 250, 500, and 1000 kHz) were used for the bioelectrical impedance analysis instrument, and we adopted a value of 50 kHz to calculate the participants’ appendicular skeletal muscle mass. The skeletal muscle mass of the participants was converted into SMI by dividing their muscle mass (kg) by the square of their height (m²). In addition, handgrip strength was assessed by handgrip strength measured using a Smedley-type handheld dynamometer (Takei Ltd, Niigata, Japan).

Gait speed was measured by walking a 6.4 m path on a flat and straight surface at a comfortable pace. Two markers were used and placed in the middle of the path to indicate the start and end of a 2.4 m walking path to measure walking speed. A 2 m section before the start marker and beyond the
marker’s end was used to ensure a consistent walking pace while on the timed path. Walking times were measured in seconds using a stopwatch with a sensor, and the participants’ walking speed (m/s) was calculated.

Active Mobility Index
The participants’ life space and related activities were assessed using AMI, and the detailed protocol has been described previously. AMI assessed physical and social activities in three levels of life space in a recent month: <1 km, 1–10 km, and >10 km from the respondent’s residence. In each area, participants were asked how often they visited the location per week (0/1–3 days/4–6 days/every day); the purpose (mainly for physical activity [such as walking and exercise] or mainly for daily chores and appointments [shopping or meeting people] both equally); transportation (walking/bicycle/bus/train/car, or other); extent of interaction with others [how many people (0/1–2/3–4/≥5)]; and extent of physical activity [how much (almost none/very little/some/a lot)].

Life space score was computed for each level by multiplying the life space level (distance of <1 km = 1, distance of 1–10 km = 2, distance of 10 km ≥ 3) and frequency (no = 0, <1 = 1, 1–3 days = 2, 4–6 days = 3, every day = 4). AMI physical and social scores were computed by multiplying the life space score and physical and social scores. Physical scores were the sum of the purpose (mainly for physical activity = 2, mainly for daily chores and appointments = 0, both 1 and 2 equally = 1), transportation (walking/bicycle = 1, bus/train/car = 0, car/other = 0), and the extent of physical activity (almost none = 0, very little = 1, some = 2, a lot = 3). Social scores were the sum of the purpose (mainly physical activity = 0, mainly daily errand = 2, both 1 and 2 equally = 1), transportation (walking/bicycle = 0, bus/train = 1, car/other = 0), and extent of interaction with others (0 = 0, 1–2 = 1, 3–4 = 2, ≥5 = 3). Each AMI physical and social score ranged from 0 to 144, with higher scores indicating greater life space with activities. According to the response to the purpose and transportation question, either physical or social score was high, or both scores were equal. The range of the AMI total score was the sum of AMI physical and social scores, from 0 to 216. The scoring sample can be found in the appendix of the original literature.

Potential confounding factors
In addition to collated data on their sociodemographic characteristics (age, sex, and years of education), participants were asked about their lifestyle and medical information through a face-to-face interview. Participants were asked about their lifestyle, drinking habits (yes/no), smoking habits (current smoking/stopped smoking/no), living alone (yes/no), and whether they drove a car (yes/no). As the medical data, number of current medications, fall history in a year (yes/no), depressive symptoms, and cognitive function were assessed. Five or more medications were identified as polypharmacy. Depressive symptoms were assessed using the 15-item Geriatric Depression Scale (GDS), consisting of 15 yes/no questions and a score ranging from 0 to 15. Six or more scores identified depressive symptoms. The MMSE was used to evaluate cognitive function. An MMSE score ≤ 23 was identified as a general cognitive impairment.

Statistical analysis
The differences in participants’ characteristics among the quartile groups of AMI total score were examined using one-way analysis of variance for continuous variables and the χ² test for discrete variables. The Cochran–Armitage trend test examined whether quartile groups of AMI total, physical, and social scores were associated with a lower prevalence of sarcopenia. The associations between the quartiles of AMI total, physical, and social scores and sarcopenia were examined using binomial logistic regression models. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of sarcopenia were calculated in the crude and fully adjusted models for all covariates. Similarly, the associations of the quartiles of AMI scores with each sarcopenia index were examined using binomial logistic regression models for sub-analysis. The Cochran–Armitage trend test was performed using the JMP statistical package Version 16 (SAS Institute, Cary, NC, USA), and the other analyses were conducted using SPSS Version 25 (IBM, New York City, NY, USA). The level of statistical significance was set at P < 0.05.

Results
The characteristics of the 21,644 participants (73.5 ± 5.8 years old, 54.7% female, and 11.8 ± 2.4 years of education) and comparison by quartile groups of AMI total score are summarized in Table 1. Compared with the higher score groups, the lower score groups were older and had a lower proportion of men (all P < 0.001), and especially Q1 group showed a higher proportion of global cognitive impairment, depressive symptoms, polypharmacy, and fall history in a year (all P < 0.001). Regarding lifestyle factors, the lower score groups showed a lower proportion of drinkers and car drivers and a higher proportion of those living alone (all P < 0.001).

The prevalence of sarcopenia among the analysed subjects was 4.1% (n = 894). The prevalence in quartile groups of AMI total, physical, and social scores is described by the bar graph in Figure 1. The Cochran–Armitage trend test indicated that higher groups of each score showed a significantly lower prevalence of sarcopenia (all P < 0.001). Odds ratios (ORs) of sarcopenia for AMI scores in the logistic regression model are summarized in Table 2. In the AMI total score, referred to Q1 group, Q3 and Q4 groups were associated with reduced aOR of sarcopenia with a significant trend after adjusting for confounders.
for all covariates (aOR 0.69–0.71, both \( P < 0.01 \)). Q3 and Q4 of the AMI physical score groups were significantly associated with reduced OR of sarcopenia (aOR 0.67–0.71, both \( P < 0.01 \)). In the AMI social score, only the Q4 group showed a reduced OR of sarcopenia (aOR 0.79, 95% CI 0.62–1.01, \( P = 0.057 \)).

The aORs of sarcopenia indices, including lower grip strength, lower muscle mass, and lower gait speed, for AMI scores in the logistic regression model are summarized in Table 3. Higher AMI total score, AMI physical score, and AMI social score were significantly associated with reduced aOR of lower grip strength and gait speed (lower grip strength: aOR 0.68–0.83, all \( P < 0.05 \); lower gait speed: aOR 0.48–0.84, all \( P < 0.01 \)). Q3 and Q4 of AMI total score and AMI physical score were associated with reduced OR of lower muscle mass with a significant trend (aOR 0.68–0.83, all \( P < 0.05 \)), while in the AMI social score, only the Q4 group was associated with lower muscle mass (aOR 0.81, 95% CI 0.68–0.96, \( P = 0.017 \)).

**Table 1** Characteristics of overall participants and comparison between groups by quartile of AMI total score

| Characteristic                        | Overall (n = 21,644) | Q1 (n = 5522) | Q2 (n = 5606) | Q3 (n = 5329) | Q4 (n = 5187) |
|--------------------------------------|----------------------|---------------|---------------|---------------|---------------|
| Age, years                           | 73.5 (5.8)           | 74.9 (6.4)    | 73.5 (5.9)    | 73.0 (5.5)    | 72.7 (5.3)    |
| Female, n (%)                        | 54.7                 | 56.4          | 56.5          | 54.7          | 50.9          |
| Education, years                     | 11.8 (2.4)           | 11.3 (2.4)    | 11.8 (2.4)    | 12.0 (2.4)    | 12.1 (2.5)    |
| BMI, kg/m²                           | 23.1 (3.1)           | 23.0 (3.3)    | 23.1 (3.1)    | 23.2 (3.0)    | 23.3 (3.0)    |
| MMSE ≤ 23 score, %                   | 9.5                  | 12.2          | 8.5           | 8.4           | 8.8           |
| GDS ≥ 6 score, %                     | 12.0                 | 21.2          | 12.0          | 9.2           | 5.2           |
| Medications ≥ 5, %                   | 23.5                 | 29.2          | 24.7          | 20.8          | 19.0          |
| Fall history, %                      | 19.5                 | 22.1          | 19.5          | 18.2          | 18.3          |
| Drinking habit, %                    | 40.9                 | 35.2          | 40.2          | 43.0          | 45.7          |
| Smoking habit, %                     |                      |               |               |               |               |
| Stopped                               | 30.2                 | 29.2          | 30.0          | 30.5          | 31.2          |
| Yes                                  | 7.6                  | 8.6           | 7.0           | 7.5           | 7.3           |
| Living alone, %                      | 12.9                 | 15.0          | 12.5          | 11.5          | 12.4          |
| Car driving, %                       | 69.6                 | 60.1          | 68.5          | 72.9          | 77.5          |
| AMI total score                      | 71.6 (29.3)          | 36.8 (10.9)   | 61.1 (5.5)    | 80.1 (5.8)    | 111.1 (18.8)  |
| AMI physical score                   | 31.4 (17.3)          | 15.1 (8.2)    | 26.5 (9.4)    | 35.3 (11.6)   | 50.0 (16.6)   |
| AMI social score                     | 40.2 (18.8)          | 21.8 (9.1)    | 34.6 (9.5)    | 44.8 (11.7)   | 61.1 (17.0)   |

AMI, Active Mobility Index; BMI, body mass index; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination. All values are reported as mean (standard deviation) or %.

*Continuous variables and category variables between groups were compared using one-way analysis of variance and \( \chi^2 \) test, respectively. All comparisons showed significant differences (all \( P < 0.001 \)).

**Figure 1** Prevalence of sarcopenia according to quartile of AMI scores. The differences between quartile groups of each score were verified using the Cochran–Armitage trend test (\( P < 0.001 \)). AMI, Active Mobility Index.

**Discussion**

The present study examined the association between AMI scores and sarcopenia among community-dwelling older adults. The findings showed that higher AMI total and AMI physical scores were associated with reduced OR of sarcopenia, and the association between AMI social scores and sarcopenia was weakened in the adjusted model. In a sub-analysis, higher AMI total, physical, and social scores were associated with a reduced OR of low grip strength and low gait speed.
## Table 2 Logistic regression model for the associations between AMI scores and sarcopenia

| Variable                  | AMI total score | AMI physical score | AMI social score |
|---------------------------|-----------------|--------------------|------------------|
|                           | Crude OR (95% CI) | Adjusted aOR (95% CI) | Crude OR (95% CI) | Adjusted aOR (95% CI) | Crude OR (95% CI) | Adjusted aOR (95% CI) |
| AMI score (ref: Q1)       |                 |                    |                  |                    |
| Q2                       | 0.61 (0.51–0.72) | <0.001             | 0.87 (0.71–1.06) | 0.167              | 0.78 (0.65–0.92) | 0.004 | 1.02 (0.83–1.25) | 0.864 | 0.75 (0.64–0.89) | 0.001 | 1.05 (0.86–1.28) | 0.650 |
| Q3                       | 0.46 (0.38–0.56) | <0.001             | 0.71 (0.57–0.89) | 0.003 | 0.58 (0.48–0.70) | <0.001 | 0.71 (0.57–0.89) | 0.003 | 0.50 (0.42–0.60) | <0.001 | 0.86 (0.70–1.07) | 0.188 |
| Q4                       | 0.46 (0.38–0.56) | <0.001             | 0.69 (0.55–0.87) | 0.002 | 0.59 (0.49–0.71) | <0.001 | 0.67 (0.54–0.84) | <0.001 | 0.42 (0.34–0.51) | <0.001 | 0.79 (0.62–1.01) | 0.057 |
| P for trend               | <0.001          | 0.003              | <0.001           | <0.001 |
| Age                      | 1.07 (1.05–1.08) | <0.001             | 1.07 (1.05–1.08) | <0.001 |
| Sex (ref: female)         | 5.96 (4.64–7.65) | <0.001             | 6.24 (4.85–8.03) | <0.001 |
| Education                 | 0.95 (0.92–0.99) | 0.006              | 0.95 (0.92–0.98) | 0.006 |
| BMI                       | 0.48 (0.46–0.50) | <0.001             | 0.48 (0.46–0.49) | <0.001 |
| Medications (ref: ≥5)     | 0.76 (0.63–0.91) | 0.003              | 0.76 (0.63–0.91) | 0.003 |
| MMSE (ref: ≤23 score)     | 0.82 (0.66–1.03) | 0.090              | 0.82 (0.66–1.03) | 0.092 |
| GDS (ref: ≥6 score)       | 0.92 (0.74–1.13) | 0.430              | 0.91 (0.74–1.13) | 0.395 |
| Fall history (ref: yes)   | 0.85 (0.70–1.03) | 0.090              | 0.85 (0.70–1.03) | 0.097 |
| Drinking habit (ref: no)  | 1.32 (1.11–1.57) | 0.002              | 1.31 (1.10–1.56) | 0.002 |
| Smoking habit (ref: no)   |                 |                    |                  |                    |
| Stopped smoking           | 0.80 (0.60–1.08) | 0.153              | 0.82 (0.61–1.11) | 0.200 |
| Current smoking           | 0.91 (0.70–1.20) | 0.519              | 0.93 (0.71–1.22) | 0.615 |
| Living alone (ref: yes)   | 0.98 (0.78–1.24) | 0.889              | 0.98 (0.77–1.24) | 0.853 |
| Driving (ref: no)         | 0.80 (0.66–0.98) | 0.031              | 0.79 (0.65–0.96) | 0.019 |

AMI, Active Mobility Index; aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; OR, odds ratio.
In addition, higher AMI total and AMI physical scores were associated with a reduced OR of lower muscle mass, while there was a weak association of AMI social score with lower muscle mass.

The findings on AMI total score and AMI physical score indicate that a larger life space with physical activity is protectively associated with sarcopenia and its indices. This is similar to other studies that reported associations between life space and physical performance, including grip strength and gait speed. In addition, a longitudinal study reported that community-dwelling older women who left the neighbourhood less frequently were inclined to engage in longer moderate and low-intensity periods in space and physical performance, including grip strength and gait speed. Although the correlation between AMI social score and physical activity has not been studied, the large life space with social activity may accompany physical activity and is associated with grip strength and gait speed. Cross-sectional studies that objectively measured physical activity using an accelerometer suggested the importance of the intensity of physical activity for sarcopenia; low-intensity physical activity showed a weak association with sarcopenia, while moderate to vigorous-intensity physical activity showed a clear association with reduced OR of sarcopenia.

Future studies should examine the association between AMI and physical activity.

The strength of the present study is that we could examine the association between AMI and sarcopenia using extensive cohort data. However, there were some limitations to our study. First, this study had a cross-sectional design and could not examine the causal relationships between AMI and sarcopenia. Future longitudinal studies are needed to examine this relationship. Second, there was a selection bias because the

Table 3 Logistic regression model for the associations between AMI scores and sarcopenia indices

| AMI scores          | Lower grip strength | Lower muscle mass | Lower gait speed |
|---------------------|---------------------|-------------------|-----------------|
|                     | aOR (95% CI)        | P                 | aOR (95% CI)    | P     | aOR (95% CI) | P     |
| AMI total score     |                     |                   |                 |       |             |       |
| Q2                  | 0.85 (0.77–0.94)    | 0.001             | 0.86 (0.73–1.02)| 0.075 | 0.70 (0.64–0.76)| <0.001|
| Q3                  | 0.72 (0.65–0.80)    | <0.001            | 0.82 (0.69–0.97)| 0.020 | 0.61 (0.56–0.67)| <0.001|
| Q4                  | 0.71 (0.64–0.79)    | <0.001            | 0.68 (0.57–0.81)| <0.001| 0.55 (0.50–0.61)| <0.001|
| P for trend         | <0.001              |                   | <0.001          |       | <0.001       |       |
| AMI physical score  |                     |                   |                 |       |             |       |
| Q2                  | 0.87 (0.79–0.96)    | 0.008             | 1.03 (0.87–1.22)| 0.694 | 0.77 (0.71–0.84)| <0.001|
| Q3                  | 0.72 (0.65–0.80)    | <0.001            | 0.83 (0.70–0.98)| 0.032 | 0.57 (0.52–0.63)| <0.001|
| Q4                  | 0.68 (0.61–0.76)    | <0.001            | 0.75 (0.64–0.89)| 0.001 | 0.48 (0.44–0.53)| <0.001|
| P for trend         | <0.001              |                   | <0.001          |       | <0.001       |       |
| AMI social score    |                     |                   |                 |       |             |       |
| Q2                  | 0.92 (0.84–1.02)    | 0.129             | 0.99 (0.84–1.17)| 0.950 | 0.84 (0.77–0.92)| <0.001|
| Q3                  | 0.89 (0.81–0.99)    | 0.029             | 0.93 (0.79–1.09)| 0.374 | 0.76 (0.69–0.83)| <0.001|
| Q4                  | 0.79 (0.71–0.89)    | <0.001            | 0.81 (0.68–0.96)| 0.017 | 0.75 (0.68–0.82)| <0.001|
| P for trend         | 0.001               |                   | 0.069           |       | <0.001       |       |

AMI, Active Mobility Index; aOR, adjusted odds ratio; CI, confidence interval.
aOR was adjusted for age, sex, education year, body mass index, medications (<5≥5), Mini-Mental State Examination score (<23/>23), Geriatric Depression Scale score (<6/>6), fall history, drinking habit, smoking habit, whether the individual lives alone, and whether the individual drives car.

DOI: 10.1002/jcsm.12994
participants were not randomly selected. They were relatively healthy and could access health check-ups from their homes, which might distort the associations between AMI and sarcopenia among community-dwelling older adults. Third, we evaluated skeletal muscle mass using a bioimpedance analyser, not the reference standard method, dual-energy X-ray absorptiometry (DXA). DXA provides a more precise measure of lean mass than the bioimpedance method, but this study could not estimate the extent of misclassified sarcopenia. Fourth, we failed to address other potential confounders affecting the progression of sarcopenia, such as nutritional intake and drug therapy.

In conclusion, AMI was associated with sarcopenia in community-dwelling older Japanese adults. Our findings indicated that a large life space, mainly with physical activity, was significantly associated with sufficient muscle strength, muscle mass, and gait speed. Future longitudinal studies are needed to confirm the causality of AMI with respect to sarcopenia and the importance of life space with activity for preventing sarcopenia.

Acknowledgements

The authors would like to thank the Obu City Office, Midori ward office, Takahama City office, Tokai City office, and Toyoake City office for help with participant recruitment. The authors certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.

References

1. 2022 ICD-10-CM diagnosis code M62.84. https://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M62-/M62.84. Accessed 4 Nov 2021.
2. Vellas B, Fielding RA, Bens C, Bernabei R, Cawthon PM, Cederholm T, et al. Implications of ICD-10 for sarcopenia clinical practice and clinical trials: report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2018;7:2–9.
3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European criteria on definition and diagnosis. Age Ageing 2018. https://doi.org/10.1093/ageing/afy169
4. Tang TC, Hwang AC, Liu LK, Lee WJ, Chen LY, Wu YH, et al. FNIH-defined sarcopenia predicts adverse outcomes among community-dwelling older people in Taiwan: results from I-Lan Longitudinal Aging Study. J Gerontol A Biol Sci Med Sci 2018;73:S28–S34.
5. Petermann-Rocha F, Gray SR, Pell JP, Celis-Morales C, Ho FK. Biomarkers profile of people with sarcopenia: a cross-sectional analysis from UK Biobank. J Am Med Dir Assoc 2020;21:2017.e1–e9.
6. Billiot M, Calvani R, Urtamo A, Sanchez-Sanchez JL, Ciccolari-Micaldi C, Chang M, et al. Preserving mobility in older adults with physical frailty and sarcopenia: opportunities, challenges, and recommendations for physical activity interventions. Clin Interv Aging 2020;15:1675–1690.
7. Montero-Fernandez N, Serra-Rexach JA. Role of exercise on sarcopenia in the elderly. Eur J Phys Rehabil Med 2013;49:131–143.
8. Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shielis K, Holmerova I. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging 2017;12:835–845.
9. Buchman AS, Boyle PA, Wilson RS, Fleischman DA, Leurgans S, Bennett DA. Association between late-life social activity and motor decline in older adults. Arch Intern Med 2009;169:1139–1146.
10. James BD, Boyle PA, Buchman AS, Bennett DA. Relation of late-life social activity with incident disability among community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2011;66:467–473.
11. Unger JB, McAvay G, Bruce ML, Berkman L, Seeman T. Variation in the impact of social network characteristics on physical functioning in elderly persons: MacArthur Studies of Successful Aging. J Gerontol B Psychol Sci Soc Sci 1999;54:S245–S251.
12. Johnson J, Rodriguez MA, Al Snih S. Life-space mobility in the elderly: current perspectives. Clin Interv Aging 2020;15:1665–1674.
13. May D, Nayak US, Isaacs B. The life-space diary: a measure of mobility in old people at home. Int Rehabil Med 1985;7:182–186.
14. Portegis E, Tsai LT, Rantanen T, Rantakokko M. Moving through life-space areas and objectively measured physical activity of older people. PLoS ONE 2015;10:e0135308. https://doi.org/10.1371/journal.pone.0135308
15. Tsai LT, Rantakokko M, Rantanen T, Viljanen A, Kauppinen M, Portegis E. Objectively measured physical activity and...
changes in life-space mobility among older people. *J Gerontol A Biol Sci Med Sci* 2016; 71:1466–1471.

16. Barnes LL, Wilson RS, Bienias JL, de Leon CF, Kim HJ, Buchman AS, et al. Correlates of life space in a volunteer cohort of older adults. *Exp Aging Res* 2007; 33:77–93.

17. Murata C, Kondo T, Tamakoshi K, Yatsuaya H, Toyoshima H. Factors associated with life space among community-living rural elders in Japan. *Public Health Nurs* 2006; 23:324–331.

18. Xue QL, Fried LP, Glass TA, Laffan A, Chaves PH. Life-space constriction, development of frailty, and the competing risk of mortality: the Women’s Health And Aging Study I. *Am J Epidemiol* 2010; 171:1466–1471.

19. Kuspinar A, Verschoor CP, Beauchamp MK, Dushoff J, Ma J, Amster E, et al. Modifiable factors related to life-space mobility in community-dwelling older adults: results from the Canadian Longitudinal Study on Aging. *BMC Geriatr* 2020; 20:35.

20. Doi T, Tsutsumimoto K, Nakakubo S, Kurita S, Ishii H, Shimada H. Associations between Active Mobility Index and disability. *J Am Med Dir Assoc* 2021. https://doi.org/10.1016/j.jamda.2021.08.036

21. Shimada H, Makizako H, Doi T, Tsutsumimoto K, Lee S, Suzuki T. Cognitive impairment and disability in older Japanese adults. *PloS ONE* 2016;11:e0158720. https://doi.org/10.1371/journal.pone.0158720

22. Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. *Am J Geriatr Psychiatry* 2006; 14:139–144.

23. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. *J Am Med Dir Assoc* 2020; 21:300–7.

24. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. *J Clin Epidemiol* 2012; 65:989–995.

25. Yesavage JA. Geriatric Depression Scale. *Psychopharmacol Bull* 1988; 24:709–711.

26. Folstein MF, Robins LN, Helzer JE. The mini-mental state examination. *Arch Gen Psychiatry* 1983; 40:812.

27. Anthony JC, LeResche L, Niaz U, von Korff MR, Folstein MF. Limits of the ‘mini-mental state’ as a screening test for dementia and delirium among hospital patients. *Psychol Med* 1982; 12:397–408.

28. Peel C, Sawyer Baker P, Roth DL, Brown CJ, Broder EF, Allman RM. Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment. *Phys Ther* 2005; 85:1008–1119.

29. Portegijs E, Rantakokko M, Mikkola TM, Viljanen A, Rantanen T. Association between physical performance and sense of autonomy in outdoor activities and life-space mobility in community-dwelling older people. *J Am Geriatr Soc* 2014; 62:615–621.

30. Tsuji T, Rantakokko M, Portegijs E, Viljanen A, Rantanen T. The effect of body mass index, lower extremity performance, and use of a private car on incident life-space restriction: a two-year follow-up study. *BMC Geriatr* 2018; 18:271.

31. Uemura K, Makizako H, Lee S, Doi T, Lee S, Tsutsumimoto K, et al. The impact of sarcopenia on incident homebound status among community-dwelling older adults: a prospective cohort study. *Maturitas* 2018; 113:26–31.

32. Sanchez-Sanchez JL, Manas A, Garcia-Garcia FJ, Ara I, Carnicero JA, Walter S, et al. Sedentary behaviour, physical activity, and sarcopenia among older adults in the TSHA: isetemporal substitution model. *J Cachexia Sarcopenia Muscle* 2019; 10:188–198.

33. Scott D, Johansson J, Gandham A, Ebeling PR, Nordstrom P, Nordstrom A. Associations of accelerometer-determined physical activity and sedentary behavior with sarcopenia and incident falls over 12 months in community-dwelling Swedish older adults. *J Sport Health Sci* 2021; 10:577–584.

34. Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. *J Cachexia Sarcopenia Muscle* 2018; 9:269–278.

35. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. *J Cachexia Sarcopenia Muscle* 2021; 12:2259–2261.